scPharmaceuticals, Inc. (NASDAQ:SCPH) is AIGH Capital Management LLC's 5th Largest Position

AIGH Capital Management LLC cut its holdings in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 1.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,096,367 shares of the company's stock after selling 78,000 shares during the quarter. scPharmaceuticals comprises 4.5% of AIGH Capital Management LLC's portfolio, making the stock its 5th biggest holding. AIGH Capital Management LLC owned 8.15% of scPharmaceuticals worth $10,773,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SCPH. Bank of New York Mellon Corp boosted its stake in scPharmaceuticals by 8.8% in the 4th quarter. Bank of New York Mellon Corp now owns 75,174 shares of the company's stock valued at $266,000 after purchasing an additional 6,051 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in scPharmaceuticals by 35.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 102,854 shares of the company's stock valued at $364,000 after purchasing an additional 26,964 shares during the period. Raymond James Financial Inc. bought a new stake in scPharmaceuticals in the 4th quarter valued at $318,000. Corebridge Financial Inc. boosted its stake in scPharmaceuticals by 29.0% in the 4th quarter. Corebridge Financial Inc. now owns 19,586 shares of the company's stock valued at $69,000 after purchasing an additional 4,406 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in scPharmaceuticals by 31.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 23,471 shares of the company's stock valued at $84,000 after purchasing an additional 5,633 shares during the period. 89.52% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Stock Performance

SCPH traded up $0.25 during trading on Tuesday, hitting $5.38. The stock had a trading volume of 305,600 shares, compared to its average volume of 380,930. The company has a 50 day moving average price of $3.94 and a 200-day moving average price of $3.30. The firm has a market cap of $284.01 million, a price-to-earnings ratio of -2.82 and a beta of 0.38. scPharmaceuticals, Inc. has a one year low of $1.94 and a one year high of $5.65. The company has a debt-to-equity ratio of 3.86, a current ratio of 5.48 and a quick ratio of 4.61.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative net margin of 216.24% and a negative return on equity of 594.07%. As a group, research analysts predict that scPharmaceuticals, Inc. will post -1.53 EPS for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.